MIPS researcher receives grant from MS Research Australia
Venom power: Scientists receive funding to develop novel drug for multiple sclerosis
Research into a modified toxin from the venom of a scorpion has led a team of Monash University scientists a step closer to preclinical trials of a new drug candidate for multiple sclerosis (MS).
MIPS medicinal chemistry platform progresses partnered research programs via the Therapeutic Innovation Australia pipeline initiative
The Australian Translational Medicinal Chemistry Facility (ATMCF) and partners have received over $500,000 in funding for five different projects as part of the Therapeutic Innovation Australia (TIA)
MIPS researchers PIK out a new drug target to reduce heart attacks
Researchers from Monash University’s Institute of Pharmaceutical Sciences (MIPS) together with other Monash and international collaborators have discovered a new target for drugs that could potentially prevent heart attacks and strokes by
Prof Jonathan Baell collaborates with PMCC on Nature publication
MIPS maintains top score in 2018 ERA rankings
The Monash Institute of Pharmaceutical Sciences has again received excellent results in the latest Excellence in Research for Australia (ERA) rankings.
PharmAlliance meets at Monash University
PharmAlliance, the research, professional practice and education partnership between the Schools of Pharmacy at Monash University, University College London (UCL) and the University of North Carolina at Chapel Hill (UNC), has held its
Faculty success in major Commonwealth grant programs
The Monash Faculty of Pharmacy and Pharmaceutical Sciences has been awarded nearly $20 million dollars in research funding in the recent rounds of grants announced by the National Health and Medical Research Council (“NHMRC”) and the